The US FDA has shelved a fast-track drug review initiative tied to the Commissioner’s National Priority Voucher program, Reuters reported, citing six sources and internal documents. Launched in June 2025, the program aimed to cut review timelines to roughly one to two months for therapies aligned with national priorities. Critics had previously warned that the pathway could enable preferential treatment. A pause to the program may signal near-term uncertainty for sponsors seeking accelerated review leverage outside standard FDA programs.